Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
Purpose
To determine the safety, pharmacokinetics (PK), and maximum-tolerated dose (MTD) up to a prespecified target dose of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients with previously untreated, nonsquamous, stage IIIb (with pleural effusion)/IV or recurrent non–small-cell lung cancer (NSCLC).
Patients and Methods
In this phase 1b study, patients (n = 24) received PCB on day 1 of each 21-day cycle then dulanermin at 4 or 8 mg/kg/d for 5 consecutive days or 15 or 20 mg/kg/d for 2 consecutive days per assigned treatment cohort. Incidence of dose-limiting toxicities (DLTs), adverse events, and antidulanermin antibodies were assessed. PK parameters were recorded for each agent. Tumor response was measured by modified Response Evaluation Criteria in Solid Tumors.
Results
Twenty-four patients received at least one dose of dulanermin plus PCB, six in each treatment cohort. There were no DLTs. An MTD was not reached, and the drug combination was well tolerated. Treatment-emergent adverse events were generally as expected for the PCB regimen. Adverse events attributed to dulanermin were grade 1/2; no significant hepatotoxicity occurred. There was minimal impact of PCB on the PK of dulanermin. There was one confirmed complete response and 13 confirmed partial responses. The overall response rate was 58% (95% CI, 37 to 78). Median progression-free survival was 7.2 months (95% CI, 4.7 to 10.3).
Conclusion
Dulanermin plus PCB was well tolerated with no occurrence of DLTs and demonstrated antitumor activity in this patient population. Dulanermin at 8 mg/kg/d for 5 days and 20 mg/kg/d for 2 days every 3 weeks in combination with PCB is being studied in a phase II trial.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Cancers
10 publications, 5.38%
|
|
|
Cancer Letters
8 publications, 4.3%
|
|
|
Oncology Reports
5 publications, 2.69%
|
|
|
Molecular Cancer Therapeutics
5 publications, 2.69%
|
|
|
Cell Death and Disease
4 publications, 2.15%
|
|
|
Cell Death and Differentiation
4 publications, 2.15%
|
|
|
Investigational New Drugs
4 publications, 2.15%
|
|
|
Journal of Controlled Release
3 publications, 1.61%
|
|
|
Cancer Medicine
3 publications, 1.61%
|
|
|
Clinical Cancer Research
3 publications, 1.61%
|
|
|
Oncotarget
2 publications, 1.08%
|
|
|
Bioanalysis
2 publications, 1.08%
|
|
|
Frontiers in Immunology
2 publications, 1.08%
|
|
|
Oncogene
2 publications, 1.08%
|
|
|
Scientific Reports
2 publications, 1.08%
|
|
|
Molecular Cancer
2 publications, 1.08%
|
|
|
Gynecologic Oncology
2 publications, 1.08%
|
|
|
Journal of Thoracic Oncology
2 publications, 1.08%
|
|
|
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
2 publications, 1.08%
|
|
|
Critical Reviews in Oncology/Hematology
2 publications, 1.08%
|
|
|
Biochemical Pharmacology
2 publications, 1.08%
|
|
|
Cancer Cell
2 publications, 1.08%
|
|
|
International Journal of Cancer
2 publications, 1.08%
|
|
|
Nanoscale
2 publications, 1.08%
|
|
|
Leukemia and Lymphoma
2 publications, 1.08%
|
|
|
Stem cells translational medicine
2 publications, 1.08%
|
|
|
ISRN Oncology
2 publications, 1.08%
|
|
|
Resistance to Targeted Anti-Cancer Therapeutics
2 publications, 1.08%
|
|
|
Frontiers in Cell and Developmental Biology
1 publication, 0.54%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
39 publications, 20.97%
|
|
|
Springer Nature
33 publications, 17.74%
|
|
|
Wiley
24 publications, 12.9%
|
|
|
MDPI
12 publications, 6.45%
|
|
|
Taylor & Francis
9 publications, 4.84%
|
|
|
American Association for Cancer Research (AACR)
9 publications, 4.84%
|
|
|
Spandidos Publications
8 publications, 4.3%
|
|
|
Frontiers Media S.A.
7 publications, 3.76%
|
|
|
Royal Society of Chemistry (RSC)
5 publications, 2.69%
|
|
|
SAGE
3 publications, 1.61%
|
|
|
American Chemical Society (ACS)
3 publications, 1.61%
|
|
|
Impact Journals
2 publications, 1.08%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.08%
|
|
|
Pleiades Publishing
2 publications, 1.08%
|
|
|
Oxford University Press
2 publications, 1.08%
|
|
|
Hindawi Limited
2 publications, 1.08%
|
|
|
Acoustical Society of America (ASA)
1 publication, 0.54%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.54%
|
|
|
The Endocrine Society
1 publication, 0.54%
|
|
|
Mary Ann Liebert
1 publication, 0.54%
|
|
|
Portland Press
1 publication, 0.54%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.54%
|
|
|
Neoplasia Press
1 publication, 0.54%
|
|
|
Institute of Biochemistry
1 publication, 0.54%
|
|
|
Korean Breast Cancer Society
1 publication, 0.54%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.54%
|
|
|
eLife Sciences Publications
1 publication, 0.54%
|
|
|
American Society of Hematology
1 publication, 0.54%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 0.54%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.